The Efficacy of Daily Salmon Oil for Adult Type 2 Asthma: An Exploratory Randomized Double-Blind Trial

Asthma is a heterogeneous chronic respiratory condition with distinct inflammatory phenotypes, including type 2-driven eosinophilic asthma. This randomized, double-blind, placebo-controlled exploratory trial investigated the effects of OmeGO^®, on respiratory outcomes in adults with type 2 asthma. Over a 20-week period, 66 participants received 6 g per day of either OmeGO^® (≥120 mg eicosapentaenoic acid (EPA), ≥180 mg docosahexaenoic acid (DHA)), or placebo. The key outcome was a composite score of moderate and severe exacerbation events. Asthma control was assessed using the Asthma Control Questionnaire-5-item (ACQ5) and the Global Initiative for Asthma (GINA) criteria. The median time to the first composite event was 37 days (95% CI 9-47) in the OmeGO group and 15 days (95% CI 12-33) in the placebo group (<i>p</i> = 0.347); 73% of the participants in the OmeGO experienced at least one exacerbation compared to 82% in the placebo group (<i>p</i> = 0.347). The weekly frequence of composite events was 0.36 per day in the OmeGO group and 0.32 in the placebo group (<i>p</i> = 0.777). Even though there are no differences in the exacerbation rates between groups, the time to first composite event should be further explored.